About Tory Foote
It is unclear whether the acute ghrelin response to food intake is normal or impaired in women with AN, and this may depend on caloric content or macronutrient composition of meals (83,88,89). Observational studies show a threshold leptin level of 1.85 ng/mL may be necessary for sufficient increases in follicle-stimulating hormone and luteinizing hormone and for the complete recovery of the reproductive system (81). The rise in leptin with increased caloric intake correlates with increasing gonadotropin levels, indicating that increasing leptin may be responsible for activation of the hypothalamic-pituitary-gonadal axis. However, these changes do not correspond to increasing body weight and BMI, suggesting further dysregulation of appetite and weight control mechanisms in AN.Thyroid hormones (thyroxine (T4) and triiodothyronine (T3)) are important regulators of metabolism that affect the function of organs throughout the body. Some studies have suggested that CRH hypersecretion may also play a role in the pathophysiology of the disorder, as central injections of CRH in animals leads to anorexia and increased motor activity , which can be reversed by CRH antagonists . This is a critical unmet need as pregnancies in women with AN, whether planned or unplanned, are at higher risk for adverse outcomes for both mother and fetus, including miscarriage, cesarean delivery, premature birth, low birth weight, and perinatal mortality . When seeking medically assisted reproduction, the majority of women with a history of an eating disorder do not report it to their providers, and the majority of providers do not screen for a history of an eating disorder 17, 18. Given the paucity of data on the efficacy and safety of testosterone therapy in men with chronic illnesses such as AN, the Endocrine Society does not provide general recommendations for testosterone therapy in patients with chronic illness. Although weight recovery is generally thought to restore GnRH pulsatility, inter-individual differences exist in the sensitivity of the hypothalamic–pituitary–gonadal axis to weight gain (and loss).
Anorexia nervosa (AN) is an eating disorder characterized by chronic undernutrition and resultant low body weight. Our objective was to systematically review adrenocortical hormone levels in anorexia nervosa. A number of hormonal responses and adaptations occur in response to starvation and low body weight including changes in adrenocortical hormones. Thyroid hormones will, in most cases, readjust, as well as gonadal hormones; however, in order to prevent further bone loss, transcutaneous oestrogen and oral gestagen are advisable on top of vitamin D and calcium supplementation. In anorexia nervosa, semi-starvation leads to multiple endocrine alterations, most of which are adaptive and reversible with weight restoration. Also, patients in early puberty have mostly not been included, especially in interventional studies, resulting in a lack of knowledge as to which long-term effects on bone structure and reproductive health could be reduced by the application of, for example, transdermal oestrogen.
To provide a comprehensive representation of cortisol, studies measuring serum cortisol, urinary cortisol, salivary cortisol, cortisol in cerebrospinal fluid, and cortisol from hair samples were included. For instance, serum morning cortisol levels are commonly used to screen for adrenal insufficiency, as cortisol levels typically peak in the morning. Out of 147 articles that were excluded, 11 studies included male subjects, 78 studies reported no data on the hormones of interest or population of interest, 9 studies were not in English, 11 studies were only abstracts (complete manuscript was not published), and 38 studies utilized previously reported study participant data. Typical hormone abnormalities in AN include growth hormone resistance with resultant low insulin-like growth factor (IGF)-1 levels, functional hypothalamic amenorrhoea, nonthyroidal illness syndrome, and altered levels of appetite-regulating hormones and adipokines, including peptide YY, leptin, and ghrelin.3,4
For example, weight restoration results in resumption of menstrual cycles in most, but not all, women with AN. An important component in the treatment of AN is the evaluation and management of its endocrine complications, including functional hypogonadotropic hypogonadism and increased fracture risk. Studies have shown that rhIGF-1, which addresses the relative IGF-1 deficiency in the disorder, followed by risedronate increases BMD at the lateral spine, but not at other skeletal sites, in women with AN and low BMD compared to placebo . Risedronate, a bisphosphonate that suppresses bone resorption, increases spine BMD by 3.2% and hip BMD by 1.9% over 12 months in women with AN . This is because bone metabolism may be compromised even after just 6–12 months of amenorrhea. It is important to note that the doses of transdermal estradiol used in these studies do not provide contraceptive benefit and that patients must be informed about this. In women with AN, an open-label weekly transdermal estradiol (0.045 mg/day) and levonorgestrel (0.015 mg/day) patch increased spine BMD over 6 months .
